Etirinotecan Pegol (NKTR-102) in the third line treatment of patients with metastatic or recurrent non-small cell lung cancer: results of a phase II study

This study evaluated etirinotecan pegol for third line treatment of patients with metastatic NSCLC. Response rate was the primary endpoint; futility would be declared if fewer than 3 responses were seen. 40 patients were enrolled, 2 partial responses were seen; prolonged disease stabilization was seen in 18 patients. Study failed to meet its primary endpoint, further studies are not planned.

from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2xRBXZ3
via IFTTT